Pfizer Inc. (NYSE:PFE) Shares Sold by Waverton Investment Management Ltd

Waverton Investment Management Ltd decreased its position in Pfizer Inc. (NYSE:PFE) by 42.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,444 shares of the biopharmaceutical company’s stock after selling 14,500 shares during the quarter. Waverton Investment Management Ltd’s holdings in Pfizer were worth $516,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Swedbank AB lifted its position in shares of Pfizer by 0.7% during the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after acquiring an additional 37,636 shares during the last quarter. Silver Oak Securities Incorporated raised its position in shares of Pfizer by 33.3% during the third quarter. Silver Oak Securities Incorporated now owns 13,967 shares of the biopharmaceutical company’s stock worth $397,000 after purchasing an additional 3,486 shares during the period. Allworth Financial LP lifted its holdings in shares of Pfizer by 4.4% during the third quarter. Allworth Financial LP now owns 117,755 shares of the biopharmaceutical company’s stock valued at $3,408,000 after purchasing an additional 4,915 shares during the last quarter. GHP Investment Advisors Inc. boosted its position in shares of Pfizer by 8.8% in the 3rd quarter. GHP Investment Advisors Inc. now owns 13,697 shares of the biopharmaceutical company’s stock valued at $396,000 after purchasing an additional 1,108 shares during the period. Finally, DekaBank Deutsche Girozentrale increased its stake in Pfizer by 1.1% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 7,398,373 shares of the biopharmaceutical company’s stock worth $214,684,000 after purchasing an additional 83,564 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Stock Up 1.6 %

Shares of Pfizer stock opened at $26.32 on Monday. The stock has a 50-day simple moving average of $26.30 and a 200-day simple moving average of $27.40. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The firm has a market cap of $149.14 billion, a price-to-earnings ratio of 18.66, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.10 earnings per share. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.54%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is 121.99%.

Analyst Ratings Changes

A number of research firms have commented on PFE. Truist Financial reduced their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. UBS Group decreased their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Guggenheim reissued a “buy” rating and set a $33.00 target price on shares of Pfizer in a research note on Monday, February 10th. Evercore ISI raised Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Bank of America reissued a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.